HBM Holdings Limited announced that, the Company has commenced collaborations on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. as part of the Company's ADC development and collaboration strategy. In 2022, the Company entered into a collaboration agreement with Duality Biologics, pursuant to which the Company shall grant the exclusive rights of its monoclonal antibodies for specific
tumor to Duality Biologics to develop the world's first-in-class ADCs based on Duality Biologics' Duality Immune Toxin Antibody Conjugate platform. The Company also entered into a license agreement with LegoChem Biosciences in 2022, over an antibody for ADC. The agreement also contemplated that the contracting parties may collaborate in developing the ADC for therapeutic applications.